1. Home
  2. MLTX vs DYN Comparison

MLTX vs DYN Comparison

Compare MLTX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLTX
  • DYN
  • Stock Information
  • Founded
  • MLTX 2021
  • DYN 1984
  • Country
  • MLTX Switzerland
  • DYN United States
  • Employees
  • MLTX N/A
  • DYN N/A
  • Industry
  • MLTX Biotechnology: Pharmaceutical Preparations
  • DYN Medicinal Chemicals and Botanical Products
  • Sector
  • MLTX Health Care
  • DYN Health Care
  • Exchange
  • MLTX Nasdaq
  • DYN Nasdaq
  • Market Cap
  • MLTX N/A
  • DYN 2.6B
  • IPO Year
  • MLTX N/A
  • DYN 2020
  • Fundamental
  • Price
  • MLTX $39.86
  • DYN $11.45
  • Analyst Decision
  • MLTX Strong Buy
  • DYN Strong Buy
  • Analyst Count
  • MLTX 8
  • DYN 12
  • Target Price
  • MLTX $80.50
  • DYN $47.73
  • AVG Volume (30 Days)
  • MLTX 428.8K
  • DYN 1.8M
  • Earning Date
  • MLTX 05-06-2025
  • DYN 05-01-2025
  • Dividend Yield
  • MLTX N/A
  • DYN N/A
  • EPS Growth
  • MLTX N/A
  • DYN N/A
  • EPS
  • MLTX N/A
  • DYN N/A
  • Revenue
  • MLTX N/A
  • DYN N/A
  • Revenue This Year
  • MLTX $103.95
  • DYN N/A
  • Revenue Next Year
  • MLTX N/A
  • DYN N/A
  • P/E Ratio
  • MLTX N/A
  • DYN N/A
  • Revenue Growth
  • MLTX N/A
  • DYN N/A
  • 52 Week Low
  • MLTX $36.52
  • DYN $10.72
  • 52 Week High
  • MLTX $58.26
  • DYN $47.45
  • Technical
  • Relative Strength Index (RSI)
  • MLTX 47.41
  • DYN 38.48
  • Support Level
  • MLTX $38.28
  • DYN $10.72
  • Resistance Level
  • MLTX $42.27
  • DYN $12.43
  • Average True Range (ATR)
  • MLTX 1.91
  • DYN 0.70
  • MACD
  • MLTX 0.31
  • DYN 0.07
  • Stochastic Oscillator
  • MLTX 58.14
  • DYN 34.93

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Share on Social Networks: